Pharma15

Pharma15 Corporation is a privately held company based in the United States that is developing next-generation radiopharmaceuticals for the treatment of prostate cancer. Pharma15 was founded by renowned radiopharmaceutical scientist Professor David Ulmert and CEO Suzanne Dance. Pharma15 is in the development phase, working to overcome resistance to Prostate-Specific Membrane Antigen (PSMA) targeting currently available or late-stage cancer therapies under development. In each case, these technologies have demonstrated highly specific targeting of receptors expressed on cancer cells without affecting healthy tissues.